Brokerages Set argenex SE (NASDAQ:ARGX) PT at $1,158.61

Shares of argenex SE (NASDAQ:ARGX) have received a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $1,158.6111.

ARGX has been the topic of a number of recent research reports. UBS Group raised shares of argenex from a “neutral” rating to a “buy” rating and raised their price objective for the company from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft downgraded argenex from a “buy” rating to a “hold” rating in a research note on Monday, August 24th. Wells Fargo & Company raised their price target on argenex from $1,350.00 to $1,415.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Truist Financial lifted their price objective on argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Finally, Citizens Jmp upped their price objective on argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a report on Tuesday, August 18th.

Institutional Trading of argenex

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its stake in argenex by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after acquiring an additional 83,568 shares during the last quarter. Wellington Management Group LLP increased its stake in argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Morgan Stanley increased its stake in argenex by 19.2% in the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after purchasing an additional 83,746 shares in the last quarter. Invesco Ltd. raised its holdings in argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after purchasing an additional 331,489 shares during the period. Finally, Sands Capital Management LLC raised its holdings in argenex by 2,046.6% in the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after purchasing an additional 340,245 shares during the period. 60.32% of the stock is owned by institutional investors.

argenex Price Performance

Shares of ARGX opened at $984.39 on Wednesday. The stock’s fifty day simple moving average is $934.10 and its 200-day simple moving average is $847.28. The firm has a market capitalization of $61.58 billion, a PE ratio of 37.80, a price-to-earnings-growth ratio of 1.02 and a beta of 0.47. argenex has a 12-month low of $661.85 and a 12-month high of $1,072.75.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping the consensus estimate of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. Analysts anticipate that argenex will post 29.13 EPS for the current year.

About argenex

argenx SE is a global biopharmaceutical company focused on developing and commercializing antibody-based medicines for patients with severe autoimmune diseases. The company’s research is centered on its antibody engineering technologies, including the SIMPLE Antibody platform and NHance technology, which are designed to identify and enhance therapeutic antibodies.

argenx’s leading product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce disease-causing immunoglobulin G antibodies.